Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Tough-to-Treat stomach cancer

NCT ID NCT07143604

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, and researchers will monitor their response and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

33 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus, with positive CLDN18.2 expression. * Disease progression on or after at least one prior regimen for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease. * Must have at least one measurable lesion assessed by the Investigator based on RECIST 1.1. * ECOG performance status of 0 or 1. * Minimum life expectancy of ≥12 weeks. * Adequate organ and bone marrow function. * Minimum body weight of 40 kg. * Sex and Contraceptive Requirements. Exclusion Criteria: * Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH +. * Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers. * CNS metastases or CNS pathology. * Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations). * Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy. * History of thromboembolic events.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Gastroesophageal junction cancer

Contacts and locations

Locations

  • Research Site

    Chelyabinsk, 454092, Russia

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Kuzmolovskiy, 188663, Russia

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 115533, Russia

  • Research Site

    Moscow, 125284, Russia

  • Research Site

    Moscow, 142770, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Nizhny Novgorod, 603126, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Volgograd, Unk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.